Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.
Sejal Shah, Molly L Tanenbaum, Alondra Loyola et al.
✦ AI-curated · Sources linked
In 30 seconds
This 12-month pilot and feasibility study evaluated intermittent scanned continuous glucose monitor (CGM) use among publicly insured youth younger than 20 years with type 2 diabetes. Thirty participants were enrolled; most were Hispanic, and mean baseline HbA1c was 10.2%. CGM use declined from 50% at three months to 23% at 12 months, while wear time fell by 6.4 days per two weeks. Mean HbA1c was 9.8% at 12 months, and median time in range decreased from 71% to 42%. The findings indicate challenges in sustaining CGM use in this population.
Key findings
- CGM use fell from 50% at three months to 23% at 12 months.
- CGM wear time decreased by 6.4 days per two weeks by 12 months.
- Mean HbA1c was 9.8% at 12 months; median time in range declined from 71% to 42%.
- Youth and parents reported moderate-to-positive attitudes toward diabetes technology.
Why it matters
The study highlights that providing CGM does not ensure sustained use among publicly insured youth with type 2 diabetes. Declining wear and time in range underscore the importance of understanding practical and contextual barriers to ongoing use. The results also suggest that approaches to supporting CGM use in this group may need to differ from those used with adults with type 2 diabetes or youth with type 1 diabetes.
What to keep in mind
This was a small pilot and feasibility study, and the abstract reports no comparison group; the findings do not establish that CGM use caused changes in HbA1c or time in range.